Global Osteoporosis Drugs Market will reach USD around 14.30 Billion by 2021: Zion Market Research

Sarasota, FL, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Zion Research has published a new report titled “Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021”. According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.

Osteoporosis is a bone disease in which a fragile bone with an increased susceptibility to fracture. Bones that commonly fracture include the backbones, the bones of the forearm, and the hip. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps. Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of medicine for osteoporosis, such as Fosamax, Actonel, Boniva, Zoledronic Acid (Reclast or Zometa) and others.

Browse through 27 Market Tables and 21 Figures spread over 110 Pages and in-depth TOC on “Global Osteoporosis Drugs Market: By Drug Class, Gender , Size, Share, Development, Trends, Segment, and Forecast 2015-2021”.

Request free Sample copy of Osteoporosis Drugs Market Report @

The global osteoporosis drugs market is witnessing noteworthy growth on account of growing geriatric population coupled with changing lifestyles impinging bone health. Furthermore, increasing the prevalence of osteoporosis in postmenopausal women and increasing investment in drug discovery and development is also driving the growth of the market. Prevalence of osteoporosis is more common with age. Around 15% of white people in their 50s and 70% of those over 80 are affected by osteoporosis diseases. It is more common in women than men. However, there are different side effects and complications associated with osteoporosis drugs such as irritable bowel syndrome, heartburn, nausea, and ulcers in the stomach. Thus, side effects of osteoporosis drugs may curb the market growth in the coming years. Nevertheless, focus on R&D for advanced development of new drugs and classes is expected to help in accentuating the market growth within the forecast period.

On the basis of drug class, the market can be segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Bisphosphonates were the leading segment and it accounted for around 48% share of total revenue generated in 2015. Bisphosphonates are commonly prescribed the drug for treatment and prevention of osteoporosis disease. Thus, this segment is expected to show strong growth within the forecast period. Parathyroid hormone therapy (PTH) was another key segment and it is expected to witness significant growth in the near future. Development of new drug classes such as PTH and RANK ligand inhibitors are projected to propel the growth of osteoporosis drug market in the coming years. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are awaiting the approval and are anticipated to drive the market growth in the years to come.

Browse the full "Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021" report at

The osteoporosis drugs market is segmented on the basis of gender such as male and female. The female segment dominated the market and is expected to exhibit significant growth in the near future. There are wide discrepancies between the incidence rate in women and men. Moreover, about 90% of the hip fractures occur in people over 50 years old.

In terms of revenue, North America constituted the largest share of the global osteoporosis drug market in 2015 and is expected to continue its dominance across the globe. The osteoporosis drug market is driven by increasing geriatric population, growing obesity, and rising prevalence of lifestyle associated diseases in the region. According to the National Osteoporosis Foundation about 54 million people in the U.S. aged above 50 years were affected by osteoporosis and low bone mass in 2013. In the U.S. more than 220,000 hip fractures are associated with osteoporosis.

Inquire more about this report @

In 2015, North America was followed by Europe in terms of revenue. Europe was the second largest regional market and is projected to witness substantial growth in the years to come. This growth is mainly attributed to the growing aged population and increasing consumer awareness about osteoporosis care. Moreover, the adoption of new technologies is expected to witness significant growth in the years to come. According to International Osteoporosis Foundation, more than 25 million people suffered from osteoporosis in 2010 and the number is expected to reach around 33.0 million by 2030 in Europe.

Asia Pacific is expected to be the fastest growing market in near future. The market is mainly driven by increasing population, rising incidence rate of osteoporosis, coupled with the rising health awareness among people especially in China, Japan, and India. According to a study on Epidemiology in Osteoporosis in Japan by the National Centre for Biotechnology Information, approximately 15 million people suffered from osteoporosis in Japan in 2011.

Request a customize report @

The Middle East & Africa regional market is expected to witness significant growth within the forecast period. Increasing population coupled with growing incidences of osteoporosis disease is primarily driving the market in this region. Latin America is another important regional market and is expected to experience significant growth over the forecast period. The growth is mainly due to technological advancement. Life expectancy in Brazil is increasing and the government is becoming progressively more involved in osteoporosis diagnosis and treatment.

Some of the key participants in osteoporosis drug market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. Major players are implementing sustainability strategies including product expansions, new product development and merger & acquisitions to gain the advantage over the competitors. For instance, drug maker Actavis Inc. agreed to acquire Warner Chilcott PLC for about USD 5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands—and shrinking its tax burden in 2013. Pipeline drugs of Merck and Pfizer are cathepsin and aprela are projected to provide growth platform these respective companies.

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn:

Follow Us Twitter:

Contact Us: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: Website:

Source:Zion Market Research